Solid Biosciences Q3 Loss Widens to $53.9M; $348.9M Cash Funds Runway Into 1H 2028
SLDB sits 72% above its 52-week low of $3.79.
Summary
Solid Biosciences posted a $53.9M third-quarter net loss on higher R&D and G&A spending, while $348.9M in cash and investments funds operations into the first half of 2028. A Type C FDA meeting on SGT-003's potential accelerated approval path is set for late Q4 2026.
Key Events · Earnings and Guidance · SLDB
-
Q3 Net Loss Widens to $53.9M
Third-quarter net loss was $53.9M versus $45.8M a year earlier, and the nine-month net loss reached $165.5M versus $124.5M.
-
Cash Runway Into 1H 2028
Cash, cash equivalents and available-for-sale securities totaled $348.9M at September 30, 2026, excluding $1.3M restricted cash, which funds operations into the first half of 2028.
-
R&D and G&A Spending Jump
R&D rose 12.2% to $43.6M in Q3, driven by SGT-003 manufacturing and clinical costs up $2.0M and SGT-212 up $2.6M; G&A rose 52.9% to $14.1M on personnel and commercial-readiness costs.
-
FDA Type C Meeting Set for Late Q4 2026
The company scheduled a Type C meeting with the FDA late in Q4 2026 to discuss the preliminary INSPIRE DUCHENNE SGT-003 data package and a potential accelerated approval pathway; 53 participants had been dosed as of November 3, 2026.
Analysis · SLDB · Life Sciences
The balance sheet is the real story here: $348.9M in cash and securities funds operations into the first half of 2028, so there is no near-term financing pressure, even as the loss widened on scaled-up spending for SGT-003 manufacturing and clinical work. The key swing factor is the Type C meeting with the FDA scheduled for late in the fourth quarter of 2026 to discuss the INSPIRE DUCHENNE data package and a potential accelerated approval pathway; the outcome will shape the SGT-003 regulatory path. Note that the company has been funding itself partly through the ATM, selling 10.5M shares for $76.5M net in the first nine months.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLDB was trading at $6.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $699.1M. The 52-week trading range was $3.79 to $11.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.